Cinacalcet
- Generic Name
- Cinacalcet
- Brand Names
- Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22F3N
- CAS Number
- 226256-56-0
- Unique Ingredient Identifier
- UAZ6V7728S
- Background
Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
- Indication
For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
- Associated Conditions
- Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 71
- Registration Number
- NCT00431496
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
- Conditions
- HypercalcemiaSecondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT00415584
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Post Transplant Study
- Conditions
- Kidney TansplantSecondary HyperparathyroidismHyperparathyroidism
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00395902
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
- Conditions
- Vascular CalcificationCalcificationKidney DiseaseNephrologyChronic Kidney DiseaseCoronary Artery CalcificationCardiovascular DiseaseChronic Renal FailureEnd Stage Renal DiseaseSecondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 360
- Registration Number
- NCT00379899
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
- Conditions
- Secondary HyperparathyroidismChronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3883
- Registration Number
- NCT00345839
The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2006-06-14
- Last Posted Date
- 2007-07-23
- Lead Sponsor
- Tufts University
- Target Recruit Count
- 17
- Registration Number
- NCT00336739
- Locations
- 🇺🇸
Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts, United States
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00261950
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 8
- Registration Number
- NCT00195936
- Locations
- 🇺🇸
Section of Pediatric Nephrology, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
- Conditions
- Nephrology
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1000
- Registration Number
- NCT00189501
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 170
- Registration Number
- NCT00135304
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.